StreetInsider.com News Articles

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 08 Jul 2026 08:00:00 -0400

BRISBANE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on July 2, 2026 to ten new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.

Four

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 08 Jul 2026 08:00:00 -0400

Four

PharmaCorp Closes Previously Announced Eight-Store Acquisition and Provides Acquisition Pipeline Update

Mon, 06 Jul 2026 07:30:00 -0400

Eight pharmacies acquired at an aggregate purchase price of approximately $24.2 million
The acquisitions increase PharmaCorp’s store count to 14 locations, more than doubling its operating footprint

SASKATOON, Saskatchewan, July 06, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX), a Canadian pharmacy acquisition and ownership platform, is pleased to announce that, further to its April 30, 2026 news release, it has completed the acquisition of all of the shares of eight PharmaChoice Canada-bannered pharmacies located in Eastern Canada (the “Acquisitions”) from two arm’s length vendor groups.

PharmaCorp Closes Previously Announced Eight-Store Acquisition and Provides Acquisition Pipeline Update

Mon, 06 Jul 2026 07:30:00 -0400

Eight pharmacies acquired at an aggregate purchase price of approximately $24.2 million
The acquisitions increase PharmaCorp’s store count to 14 locations, more than doubling its operating footprint

PharmaCorp Closes Previously Announced Eight-Store Acquisition and Provides Acquisition Pipeline Update

Mon, 06 Jul 2026 07:30:00 -0400

Eight pharmacies acquired at an aggregate purchase price of approximately $24.2 million
The acquisitions increase PharmaCorp’s store count to 14 locations, more than doubling its operating footprint

PharmaCorp Closes Previously Announced Eight-Store Acquisition and Provides Acquisition Pipeline Update

Mon, 06 Jul 2026 07:30:00 -0400

Eight pharmacies acquired at an aggregate purchase price of approximately $24.2 million
The acquisitions increase PharmaCorp’s store count to 14 locations, more than doubling its operating footprint

UnitedHealthcare to separately reimburse Pacira's EXPAREL drug

Wed, 01 Jul 2026 08:01:46 -0400

Pacira BioSciences (NASDAQ: PCRX) announced that UnitedHealthcare will now provide separate reimbursement for EXPAREL (bupivacaine liposome injectable suspension) across outpatient settings, including hospital outpatient departments and ambulatory surgery centers.

The change allows EXPAREL to be reimbursed outside of the surgical bundle for eligible UnitedHealthcare members. UnitedHealthcare covers approximately 40 million lives and is the largest health insurer in the United States.

UnitedHealthcare joins a list of national payers that already provide separate reimbursement for EXPAREL, including Aetna, Cigna, TRICARE, and Humana, as well as numerous regional plans. According to the company, approximately 150 million covered lives now have access to separate reimbursement

Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®

Wed, 01 Jul 2026 08:00:00 -0400

-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings --

BRISBANE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that UnitedHealthcare now provides separate reimbursement for EXPAREL^® (bupivacaine liposome injectable suspension) across outpatient settings, including hospital outpatient departments and ambulatory surgery centers. This update enables EXPAREL to be reimbursed outside of the surgical bundle for eligible UnitedHealthcare members, representing an additional step in expanding access to non-opioid postsurgical pain management

Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®

Wed, 01 Jul 2026 08:00:00 -0400

-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings --

H.C. Wainwright Reiterates Buy Rating on Pacira Pharmaceuticals (PCRX)

Wed, 01 Jul 2026 06:59:39 -0400

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $38.00 price target on Pacira Pharmaceuticals (NASDAQ: PCRX).

The analyst commented: "Yesterday, Pacira announced the divestiture of iovera to Zimmer Biomet (ZBH; not rated), one of the leading medical device manufacturers in the world. Recall, iovera is a medical device that relieves pain via cryoneurolysis. Under the terms of the transaction, Pacira will receive up to $140 million with an upfront payment of $70 million and potential future revenue-based milestone payments totaling up to an additional $70 million during the period up to and through December 31, 2031. Of particular note,

Form 8-K Pacira BioSciences, Inc. For: Jun 28

Tue, 30 Jun 2026 07:32:00 -0400

si-local-file:///var/storage/secattach/20260630/26709580.html

Form 8-K Pacira BioSciences, Inc. For: Jun 28

Tue, 30 Jun 2026 07:32:00 -0400

si-local-file:///var/storage/secattach/20260630/26709580.html

Pacira BioSciences to sell iovera° unit to Zimmer Biomet for up to $140M

Tue, 30 Jun 2026 07:31:52 -0400

Pacira BioSciences, Inc. (Nasdaq: PCRX) has agreed to divest its iovera° business to Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) for up to $140 million, according to a company statement.

Under the terms of the deal, Pacira will receive an upfront payment of $70 million, with up to an additional $70 million in potential revenue-based milestone payments through December 31, 2031. Zimmer Biomet will acquire all rights, titles, and interests for the development, manufacture, and commercialization of iovera°.

The iovera° system is an FDA-cleared medical device that uses cryoneurolysis — the application of focused cold therapy to a targeted nerve —

Pacira BioSciences to sell iovera° unit to Zimmer Biomet for up to $140M

Tue, 30 Jun 2026 07:31:52 -0400

Pacira BioSciences, Inc. (Nasdaq: PCRX) has agreed to divest its iovera° business to Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) for up to $140 million, according to a company statement.

The iovera° system is an FDA-cleared medical device that uses cryoneurolysis — the application of focused cold therapy to a targeted nerve —

Pacira BioSciences to sell iovera° unit to Zimmer Biomet for up to $140M

Tue, 30 Jun 2026 07:31:52 -0400

Pacira BioSciences, Inc. (Nasdaq: PCRX) has agreed to divest its iovera° business to Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) for up to $140 million, according to a company statement.

The iovera° system is an FDA-cleared medical device that uses cryoneurolysis — the application of focused cold therapy to a targeted nerve —

Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet

Tue, 30 Jun 2026 07:30:00 -0400

-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million in potential future revenue-based milestone payments --

-- Two companies will collaborate on advancing the spasticity program --

-- Supports 5x30 strategy and advances Pacira’s transition into an innovative biopharmaceutical company --

BRISBANE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the divestiture of iovera_®° to Zimmer Biomet

Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet

Tue, 30 Jun 2026 07:30:00 -0400

-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million in potential future revenue-based milestone payments --

-- Two companies will collaborate on advancing the spasticity program --

-- Supports 5x30 strategy and advances Pacira’s transition into an innovative biopharmaceutical company --

Form 4 Pacira BioSciences, Inc. For: Jun 11 Filed by: RIKER LAUREN

Fri, 12 Jun 2026 21:08:00 -0400

si-local-file:///var/storage/secattach/20260612/26642687.html

Form 4 Pacira BioSciences, Inc. For: Jun 11 Filed by: RIKER LAUREN

Fri, 12 Jun 2026 21:08:00 -0400

si-local-file:///var/storage/secattach/20260612/26642687.html

Form 4 Pacira BioSciences, Inc. For: Jun 10 Filed by: Hirawat Samit

Fri, 12 Jun 2026 21:08:00 -0400

si-local-file:///var/storage/secattach/20260612/26642688.html

Form 4 Pacira BioSciences, Inc. For: Jun 10 Filed by: Hirawat Samit

Fri, 12 Jun 2026 21:08:00 -0400

si-local-file:///var/storage/secattach/20260612/26642688.html

Form 4 Pacira BioSciences, Inc. For: Jun 10 Filed by: Froimson Mark

Fri, 12 Jun 2026 21:07:00 -0400

si-local-file:///var/storage/secattach/20260612/26642680.html

Form 4 Pacira BioSciences, Inc. For: Jun 10 Filed by: Froimson Mark

Fri, 12 Jun 2026 21:07:00 -0400

si-local-file:///var/storage/secattach/20260612/26642680.html

Form 4 Pacira BioSciences, Inc. For: Jun 10 Filed by: Brege Laura

Fri, 12 Jun 2026 21:07:00 -0400

si-local-file:///var/storage/secattach/20260612/26642681.html

Form 4 Pacira BioSciences, Inc. For: Jun 10 Filed by: Brege Laura

Fri, 12 Jun 2026 21:07:00 -0400

si-local-file:///var/storage/secattach/20260612/26642681.html